GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. Co.'s proprietary glycomimetics platform is based on its capabilities in carbohydrate chemistry. Co. is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, a life-threatening hematologic cancer, and potentially other hematologic cancers. Co. is also developing a drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. The GLYC stock yearly return is shown above.
The yearly return on the GLYC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GLYC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|